Literature DB >> 30108830

Facilitating the presentation of antigen peptides on dendritic cells for cancer immunotherapy using a polymer-based synthetic receptor.

Cuicui Li1, Masafumi Takeo1, Masayoshi Matsuda1, Hiroko Nagai1, Sun Xizheng1, Wataru Hatanaka2, Akihiro Kishimura1,2,3,4, Hiroyuki Inoue5, Kenzaburo Tani5, Takeshi Mori1,2,3, Yoshiki Katayama1,2,3,4,6,7.   

Abstract

The introduction of proteins into dendritic cells (DCs) ex vivo is a critical step for the DC-based immunotherapy of cancer. Here, we developed a biotin-modified polymer with multiple hydrophobic membrane anchors for cells that functions as a synthetic receptor for an antigen protein, ovalbumin (OVA), to introduce it efficiently into DCs compared with the conventional pulsing method. Our method showed significant advantages, including the rapid incorporation of OVA and the activation of antigen-specific T cells in a MHC-restricted manner. When mice were immunized by DCs treated with our method, tumor growth was completely suppressed, indicating that our method can be used to prepare adjuvant DCs.

Entities:  

Year:  2017        PMID: 30108830      PMCID: PMC6072308          DOI: 10.1039/c7md00188f

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  24 in total

Review 1.  Towards a systems understanding of MHC class I and MHC class II antigen presentation.

Authors:  Jacques Neefjes; Marlieke L M Jongsma; Petra Paul; Oddmund Bakke
Journal:  Nat Rev Immunol       Date:  2011-11-11       Impact factor: 53.106

Review 2.  Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.

Authors:  Paul J Tacken; I Jolanda M de Vries; Ruurd Torensma; Carl G Figdor
Journal:  Nat Rev Immunol       Date:  2007-10       Impact factor: 53.106

3.  Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.

Authors:  Z Shen; G Reznikoff; G Dranoff; K L Rock
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

4.  Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells.

Authors:  Rong-Fu Wang; Helen Y Wang
Journal:  Nat Biotechnol       Date:  2002-02       Impact factor: 54.908

5.  Rapid and serum-insensitive endocytotic delivery of proteins using biotinylated polymers attached via multivalent hydrophobic anchors.

Authors:  Kyohei Tobinaga; Cuicui Li; Masafumi Takeo; Masayoshi Matsuda; Hiroko Nagai; Takuro Niidome; Tatsuhiro Yamamoto; Akihiro Kishimura; Takeshi Mori; Yoshiki Katayama
Journal:  J Control Release       Date:  2013-12-31       Impact factor: 9.776

6.  Saturated fatty acids activate TLR-mediated proinflammatory signaling pathways.

Authors:  Shurong Huang; Jennifer M Rutkowsky; Ryan G Snodgrass; Kikumi D Ono-Moore; Dina A Schneider; John W Newman; Sean H Adams; Daniel H Hwang
Journal:  J Lipid Res       Date:  2012-07-04       Impact factor: 5.922

Review 7.  Physical methods for intracellular delivery: practical aspects from laboratory use to industrial-scale processing.

Authors:  J Mark Meacham; Kiranmai Durvasula; F Levent Degertekin; Andrei G Fedorov
Journal:  J Lab Autom       Date:  2013-06-27

8.  A Generic Polymer-Protein Ligation Strategy for Vaccine Delivery.

Authors:  Lien Lybaert; Nane Vanparijs; Kaat Fierens; Martijn Schuijs; Lutz Nuhn; Bart N Lambrecht; Bruno G De Geest
Journal:  Biomacromolecules       Date:  2016-02-03       Impact factor: 6.988

9.  Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors.

Authors:  D M Ashley; B Faiola; S Nair; L P Hale; D D Bigner; E Gilboa
Journal:  J Exp Med       Date:  1997-10-06       Impact factor: 14.307

10.  A Lipid Based Antigen Delivery System Efficiently Facilitates MHC Class-I Antigen Presentation in Dendritic Cells to Stimulate CD8(+) T Cells.

Authors:  Mithun Maji; Saumyabrata Mazumder; Souparno Bhattacharya; Somsubhra Thakur Choudhury; Abdus Sabur; Md Shadab; Pradyot Bhattacharya; Nahid Ali
Journal:  Sci Rep       Date:  2016-06-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.